Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats

Masataka Enomoto; Patrick W. Mantyh; Joanna Murrell; John F. Innes; B. Duncan X. Lascelles

doi:10.1136/vr.104590

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats

Masataka Enomoto, Patrick W. Mantyh, Joanna Murrell, John F. Innes, B. Duncan X. Lascelles^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article (Academic Journal) › peer-review

33 Citations (Scopus)

313 Downloads (Pure)

Abstract

Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.

Original language	English
Article number	23
Number of pages	14
Journal	Veterinary Record
Volume	184
Issue number	1
Early online date	27 Oct 2018
DOIs	https://doi.org/10.1136/vr.104590
Publication status	Published - 5 Jan 2019

Keywords

cytokines
monoclonal antibody
nerve growth factor
osteoarthritis
pain

Access to Document

10.1136/vr.104590

Full-text PDF (final published version)
This is the final published version of the article (version of record). It first appeared online via BMJ Publishing at https://veterinaryrecord.bmj.com/content/184/1/23 . Please refer to any applicable terms of use of the publisher.
Final published version, 1.14 MBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

@article{74890a71dedb4ae99274c0c2cf99b085,

title = "Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats",

abstract = "Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.",

keywords = "cytokines, monoclonal antibody, nerve growth factor, osteoarthritis, pain",

author = "Masataka Enomoto and Mantyh, {Patrick W.} and Joanna Murrell and Innes, {John F.} and Lascelles, {B. Duncan X.}",

year = "2019",

month = jan,

day = "5",

doi = "10.1136/vr.104590",

language = "English",

volume = "184",

journal = "Veterinary Record",

issn = "0042-4900",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats

AU - Enomoto, Masataka

AU - Mantyh, Patrick W.

AU - Murrell, Joanna

AU - Innes, John F.

AU - Lascelles, B. Duncan X.

PY - 2019/1/5

Y1 - 2019/1/5

N2 - Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.

AB - Nerve growth factor (NGF) is essential for the survival of sensory and sympathetic neurons during development. However, in the adult, NGF and its interaction with tropomyosin receptor kinase A receptor (TrkA) has been found to play a critical role in nociception and nervous system plasticity in pain conditions. Thus, various monoclonal antibody (mAb) therapies targeting this pathway have been investigated in the development of new pharmacotherapies for chronic pain. Although none of the mAbs against NGF are yet approved for use in humans, they look very promising for the effective control of pain. Recently, species-specific anti-NGF mAbs for the management of osteoarthritis (OA)-associated pain in dogs and cats has been developed, and early clinical trials have been conducted. Anti-NGF therapy looks to be both very effective and very promising as a novel therapy against chronic pain in dogs and cats. This review outlines the mechanism of action of NGF, the role of NGF in osteoarthritis, research in rodent OA models and the current status of the development of anti-NGF mAbs in humans. Furthermore, we describe and discuss the recent development of species-specific anti-NGF mAbs for the treatment of OA-associated pain in veterinary medicine.

KW - cytokines

KW - monoclonal antibody

KW - nerve growth factor

KW - osteoarthritis

KW - pain

UR - http://www.scopus.com/inward/record.url?scp=85056123313&partnerID=8YFLogxK

U2 - 10.1136/vr.104590

DO - 10.1136/vr.104590

M3 - Review article (Academic Journal)

C2 - 30368458

AN - SCOPUS:85056123313

VL - 184

JO - Veterinary Record

JF - Veterinary Record

SN - 0042-4900

IS - 1

M1 - 23

ER -

Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats

Abstract

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this